Share on StockTwits

Salix Pharmaceuticals (NASDAQ:SLXP) is scheduled to issue its Q214 quarterly earnings data on Thursday, August 7th. Analysts expect the company to announce earnings of $1.69 per share and revenue of $397.06 million for the quarter. Salix Pharmaceuticals has set its Q2 guidance at approx $1.63 EPS and its FY14 guidance at approx $6.33 EPS.

Salix Pharmaceuticals (NASDAQ:SLXP) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.05 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.91 by $0.14. The company had revenue of $384.00 million for the quarter, compared to the consensus estimate of $372.91 million. During the same quarter last year, the company posted $0.63 earnings per share. Salix Pharmaceuticals’s revenue was up 89.7% compared to the same quarter last year. On average, analysts expect Salix Pharmaceuticals to post $6.52 EPS for the current fiscal year and $7.09 EPS for the next fiscal year.

Salix Pharmaceuticals (NASDAQ:SLXP) opened at 137.23 on Wednesday. Salix Pharmaceuticals has a 52-week low of $64.93 and a 52-week high of $141.81. The stock has a 50-day moving average of $130.6 and a 200-day moving average of $112.7. The company has a market cap of $8.701 billion and a P/E ratio of 115.68.

A number of analysts have recently weighed in on SLXP shares. Analysts at Deutsche Bank initiated coverage on shares of Salix Pharmaceuticals in a research note on Tuesday, July 22nd. They set a “hold” rating and a $139.00 price target on the stock. On the ratings front, analysts at Zacks upgraded shares of Salix Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Monday, July 21st. They now have a $158.00 price target on the stock. Finally, analysts at Sterne Agee raised their price target on shares of Salix Pharmaceuticals from $130.00 to $165.00 in a research note on Friday, July 11th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $132.98.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.